CLINICAL EXPERIENCE WITH USTEKINUMAB IN THE TREATMENT OF EARLY PSORIATIC ARTHRITIS USING TREAT-TO-TARGET STRATEGY
The new Treat-to-Target (T2T) strategy in the treatment of early psoriatic arthritis (PsA) is aimed at achieving remission or low disease activity. As of now, the new biological agent ustekinumb (UST), anti-interleukin (IL) 12/23 monoclonal antibodies, was used to treat psoriasis and PsA. The paper...
Main Authors: | E. Yu. Loginova, T. V. Korotaeva, D. E. Karateev, E. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2015-09-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2099 |
Similar Items
-
Characteristics of patients with psoriatic arthritis treated with ustekinumab. Evidence from real-life clinical practice
by: Yu. L. Korsakova, et al.
Published: (2021-01-01) -
RESULTS OF USTEKINUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION ACCORDING TO THE DATA OF PSUMMIT 1 AND PSUMMIT 2
by: Yu. L. Korsakova, et al.
Published: (2015-04-01) -
TREAT-TO-TARGET STRATEGY FOR EARLY PSORIATIC ARTHRITIS (PRELIMINARY RESULTS OF THE REMARCА STUDY)
by: T. V. Korotaeva, et al.
Published: (2016-12-01) -
TREAT-TO-TARGET STRATEGY FOR EARLY PSORIATIC ARTHRITIS (PRELIMINARY RESULTS OF THE REMARCА STUDY)
by: T. V. Korotaeva, et al.
Published: (2014-09-01) -
2-years outcomes of the treat-to-target strategy in early psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-11-01)